CRVO — CervoMed Income Statement
0.000.00%
Last trade - 00:00- $89.20m
- $50.28m
- $9.74m
- 25
- 15
- 37
- 14
Annual income statement for CervoMed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 7.14 | 9.74 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16 | 24.7 | 16 | 15 | 28 |
| Operating Profit | -16 | -24.7 | -16 | -7.81 | -18.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.9 | -24.5 | -15.6 | -2.17 | -16.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.2 | -24.1 | -15.6 | -2.17 | -16.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.2 | -24.1 | -15.6 | -2.17 | -16.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.1 | -24.1 | -15.6 | -2.17 | -16.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -22.5 | -14.2 | -11.5 | -0.515 | -2.02 |